Molecular Response (MRL) Announces Key Agreement in Translational Oncology with OncoMed Pharmaceuticals, Inc.

Published: Feb 21, 2012

SAN DIEGO--(BUSINESS WIRE)--Molecular Response (MRL), a privately held molecular diagnostic services company and a leader in the identification of target populations for high value therapeutics, announced today an agreement with OncoMed Pharmaceuticals, Inc., significantly expanding the companies’ successful pilot program to develop unique patient-derived tumor xenografts (PDX), through the use of Molecular Response’s proprietary ‘living’ cell bank of primary tumor cells.

Back to news